Please login to the form below

Not currently logged in
Email:
Password:

Ozempic

This page shows the latest Ozempic news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk shareholder revolt reaches Europe

Novo Nordisk shareholder revolt reaches Europe

Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.

Latest news

  • Novo Nordisk boosted by new type 2 diabetes launches Novo Nordisk boosted by new type 2 diabetes launches

    Other analysts believe the drug could top that figure, with some predicting that Ozempic could reach $3bn plus at its peak. ... These trials will investigate the use of Ozempic in different settings and fordifferent outcomes, as itcontinuesto gain

  • Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12% Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

    Ozempic has been growing quickly since launch and brought in DKK 1.4bn ($211m) in the first quarter of this year. ... It is already trumpeting data showing Ozempic seems to be superior to Trulicity in maintaining glucose control when added to background

  • Pricing pressures peg back Lilly’s growth products Pricing pressures peg back Lilly’s growth products

    For Trulicity, rival Ozempic (semaglutide) from Novo Nordisk is starting to gain ground thanks to new cardiovascular outcomes data, while Taltz is expected to face a tough challenge from AbbVie’s

  • Novo uses voucher for speedy answer on oral semaglutide Novo uses voucher for speedy answer on oral semaglutide

    Oral version of Ozempic could be diabetes market leader. Novo Nordisk has filed its tablet form of diabetes injection Ozempic with the US FDA yesterday, and has used a priority review ... Novo Nordisk also submitted an sNDA for the same indication for

  • Trulicity’s ascent lifts Lilly Trulicity’s ascent lifts Lilly

    year. That means 2019 could see Trulicity overtake its rival, though Novo Nordisk has its next generation weekly GLP-1 Ozempic on the market, with an oral version also close to

More from news
Approximately 8 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics